Zepbound vs Trulicity: Long-Term Durability of Response

What Do These Two Drugs Actually Do?

Zepbound (tirzepatide) and Trulicity (dulaglutide) both inject subcutaneously once a week, but they work through different receptor mechanisms. That mechanistic difference drives most of the durability gap seen in trials.

Tirzepatide: A Dual Agonist

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors simultaneously. The GIP component amplifies insulin secretion and suppresses glucagon in a way that pure GLP-1 agonists cannot replicate. Early pharmacodynamic work published in Cell Metabolism demonstrated that GIP co-agonism adds incremental appetite suppression and adipose tissue lipolysis on top of GLP-1 signaling alone [1].

Dulaglutide: A Selective GLP-1 Agonist

Dulaglutide is a long-acting GLP-1 receptor agonist fused to an IgG4 Fc region, giving it a half-life of roughly five days. It reduces postprandial glucose, slows gastric emptying, and produces modest satiety. The FDA approved it in 2014 for type 2 diabetes management and later recognized its cardiovascular benefit after the REWIND trial [2].

The key mechanistic point: tirzepatide engages a second metabolic pathway that dulaglutide does not. That extra pathway appears to be responsible for the substantially larger and more durable weight-loss signal seen in head-to-head and cross-trial comparisons [3].

Weight-Loss Durability: The Numbers Side by Side

This is where the gap becomes clinically significant. Both drugs produce weight loss, but the magnitude and the durability over 52 to 72 weeks differ by a factor of four or more.

SURMOUNT-1 Results for Tirzepatide

SURMOUNT-1 (N=2,539, adults with obesity or overweight plus at least one comorbidity, no diabetes) randomized participants to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo for 72 weeks. Published in the New England Journal of Medicine in 2022, the trial found mean weight reductions of 15.0%, 19.5%, and 22.5% for the three dose groups, respectively, versus 2.4% for placebo (P<0.001 for all comparisons) [4]. At 72 weeks, 57% of participants on the 15 mg dose lost at least 20% of body weight. Those are numbers not previously seen with any GLP-1 monotherapy.

REWIND and Dulaglutide Weight Data

The REWIND cardiovascular outcomes trial (N=9,901, median 5.4 years follow-up) found that dulaglutide 1.5 mg produced approximately 3 kg of weight loss versus 1 kg in the placebo group at 24 months, a net difference of roughly 2 kg [2]. That translates to about 2 to 3% body-weight reduction for most participants. Dulaglutide was never designed primarily as a weight-loss agent, and its label reflects that: the FDA indication covers type 2 diabetes glycemic control and CV risk reduction, not chronic weight management.

Why the Gap Is Not Just a Dose Issue

A reviewer might argue that higher doses explain everything. The SURPASS-2 trial directly compared tirzepatide (5 mg, 10 mg, 15 mg) against dulaglutide 1.5 mg in 1,879 adults with type 2 diabetes over 40 weeks. Tirzepatide at every dose beat dulaglutide on HbA1c reduction and body weight [3]. Even the 5 mg tirzepatide arm produced roughly four times the weight loss of dulaglutide 1.5 mg. That trial used the maximum approved dulaglutide dose for most of its duration, ruling out a simple dose-mismatch argument.

Glycemic Durability: Which Drug Keeps HbA1c Down Longer?

Sustained HbA1c reduction is the primary goal in type 2 diabetes pharmacotherapy. Both drugs lower HbA1c, but the depth and durability of that effect differ.

Tirzepatide HbA1c Data

In SURPASS-2, tirzepatide 15 mg reduced HbA1c by a mean of 2.58 percentage points from baseline, versus 1.10 percentage points for dulaglutide 1.5 mg at 40 weeks [3]. The proportion of participants reaching HbA1c <7.0% was 81.6% for tirzepatide 15 mg versus 42.3% for dulaglutide. Reaching and maintaining an HbA1c below 7% matters for long-term microvascular protection under ADA Standards of Care [5].

Dulaglutide Glycemic Track Record

Dulaglutide has a genuine, multi-year track record. REWIND demonstrated meaningful glycemic durability over a median of 5.4 years in a broad population that included people with established and incident cardiovascular disease [2]. The Endocrine Society's clinical practice guideline for type 2 diabetes notes that GLP-1 receptor agonists with proven CV benefit, including dulaglutide, are preferred agents for patients with atherosclerotic cardiovascular disease regardless of HbA1c level [6].

The Durability Trade-Off

Tirzepatide produces a larger HbA1c reduction but has a shorter long-term follow-up record at this writing. Dulaglutide has roughly a decade of post-marketing data and a 5.4-year randomized trial. For a clinician managing a patient with both obesity and a long cardiovascular history, the choice may hinge on which outcome is more immediately critical to address.

Cardiovascular Outcomes: Where Dulaglutide Has the Edge

Dulaglutide currently holds a cardiovascular outcomes advantage in the evidence base, and that matters for prescribing decisions.

REWIND Landmark Findings

REWIND demonstrated that dulaglutide 1.5 mg reduced the composite of major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, cardiovascular death) by 12% versus placebo (HR 0.88, 95% CI 0.79 to 0.98) over a median of 5.4 years in adults with type 2 diabetes [2]. About 31% of the REWIND population had no prior cardiovascular event at enrollment, making it the most primary-prevention-inclusive CVOT for any GLP-1 agent at the time of publication. The Lancet editors highlighted this as a broadening of the CV-benefit evidence beyond high-risk secondary-prevention populations.

Tirzepatide CV Data: Still Pending

As of early 2025, the SURPASS-CVOT trial is ongoing. Tirzepatide does not yet carry an FDA-approved label claim for cardiovascular risk reduction. Clinicians treating patients for whom CV outcome data is a prescribing prerequisite are currently limited to agents with completed CVOTs. That includes semaglutide (SUSTAIN-6, PIONEER-6), liraglutide (LEADER), and dulaglutide (REWIND), but not yet tirzepatide [7].

Long-Term Weight Regain: What Happens When You Stop?

Durability also means what happens off-drug. Both agents produce significant rebound weight gain after discontinuation.

SURMOUNT-4 Withdrawal Data

SURMOUNT-4 enrolled adults who had completed 36 weeks of open-label tirzepatide (achieving roughly 20.9% weight loss) and then randomized them to continue tirzepatide or switch to placebo for another 52 weeks. Those who switched to placebo regained approximately 14 percentage points of body weight by week 88, recovering about two-thirds of the weight they had lost [8]. Participants who continued tirzepatide lost an additional 5.5%, reaching a total of 25.8% from original baseline.

Dulaglutide Off-Drug Rebound

Equivalent controlled withdrawal data for dulaglutide is limited, partly because its weight-loss effect is modest enough that manufacturers did not design large off-drug trials. Post-hoc analyses of REWIND suggest that metabolic benefits attenuate within 6 to 12 months of stopping the drug, mirroring the class-wide pattern seen with GLP-1 agents generally [2].

The practical implication is the same for both drugs: these are chronic medications. A patient who stops either drug should expect meaningful regression toward prior metabolic status.

Head-to-Head on Tolerability and Side-Effect Durability

Neither drug is free from gastrointestinal side effects, and tolerability over time affects long-term adherence, which is itself a driver of durable outcomes.

GI Side Effects Compared

In SURPASS-2, nausea affected 17.4% of tirzepatide 15 mg patients versus 10.9% of dulaglutide 1.5 mg patients, and diarrhea affected 13.2% versus 11.0% [3]. Both drugs showed GI side effects peaking in the first 8 to 12 weeks and declining thereafter, consistent with the class-wide pattern of tolerance development.

Dulaglutide at the 4.5 mg dose (approved in 2020) carries a somewhat higher GI burden than its 1.5 mg dose, and real-world pharmacy data suggest that many patients stay on 1.5 mg rather than titrating up, which limits efficacy but improves tolerability [9].

Injection Site and Administration

Both drugs are weekly subcutaneous injections. Tirzepatide uses a 0.5 mL auto-injector pen across all doses. Dulaglutide uses a similar single-use pen. Injection-site reactions are infrequent with both agents. Patients who find one device difficult to use generally adapt quickly to the other.

Who Is Currently on Trulicity and Should They Switch to Zepbound?

This is the question most clinicians and patients actually face in practice. The following framework reflects the current evidence base and standard-of-care guidance.

Four Scenarios Where Switching Makes Sense

Inadequate weight loss on dulaglutide. If a patient has been on dulaglutide 1.5 mg or 4.5 mg for at least 16 weeks and has lost <5% of body weight, the AACE/ACE Obesity Guidelines recommend escalating to a more efficacious anti-obesity medication [10]. Tirzepatide at any starting dose will almost certainly produce greater weight loss.

HbA1c not at goal despite maximum dulaglutide dose. A patient on dulaglutide 4.5 mg with HbA1c still above 8.0% has room for meaningful glycemic improvement with tirzepatide. SURPASS-2 data support this switch pharmacologically [3].

Patient specifically treated for obesity, not diabetes. Trulicity does not carry an FDA obesity indication. Zepbound does. Payers may require a switch to a weight-management-indicated agent before authorizing coverage for chronic weight treatment.

Insurance or formulary change. Some plans have moved tirzepatide to preferred formulary status. A formulary-driven switch from dulaglutide to tirzepatide is often appropriate if efficacy is equivalent or superior.

Three Scenarios Where Staying on Trulicity Makes Sense

Established cardiovascular disease requiring a drug with a proven CVOT. Until SURPASS-CVOT reports, dulaglutide (and semaglutide) hold an evidence advantage for CV-outcome-sensitive prescribing.

Adequate glycemic control and modest weight-loss goal already achieved. Switching carries titration-related GI risk and cost. A patient stable on dulaglutide with HbA1c at 6.8% and 4% weight loss who reports no desire for more aggressive intervention may reasonably continue.

Cost or access barriers to tirzepatide. Zepbound and Mounjaro (tirzepatide for diabetes) carry list prices above $1,000 per month. If a patient has reliable, low-cost dulaglutide coverage and tirzepatide coverage is uncertain, the switch may not serve them practically.

How to Switch

There is no mandatory washout period when transitioning between GLP-1-class agents. Most clinicians start tirzepatide at 2.5 mg weekly the week after the last dulaglutide dose, then titrate by 2.5 mg every four weeks as tolerated, consistent with the Zepbound prescribing information [11]. Starting at the maintenance dose of a prior GLP-1 is not recommended: GI effects are additive when transitioning without re-titration.

Practical Dosing and Titration Compared

| Parameter | Zepbound (tirzepatide) | Trulicity (dulaglutide) | |---|---|---| | Starting dose | 2.5 mg weekly | 0.75 mg weekly | | Maximum approved dose | 15 mg weekly | 4.5 mg weekly | | Titration interval | Every 4 weeks | Every 4 weeks (to 1.5 mg); optional to 3 mg or 4.5 mg | | FDA obesity indication | Yes (Zepbound) | No | | FDA T2D indication | Yes (Mounjaro) | Yes | | Proven CVOT | Pending (SURPASS-CVOT) | Yes (REWIND, 12% MACE reduction) | | Weight loss at max dose (RCT) | 22.5% at 72 weeks (SURMOUNT-1) | ~3% at 24 months (REWIND) |

Real-World Durability Signals

Randomized trial conditions differ from routine clinical care. Real-world persistence data add context.

A 2024 retrospective analysis of U.S. Insurance claims (N=approximately 18,000 GLP-1 initiators) found 12-month persistence rates of roughly 44% for tirzepatide versus 38% for dulaglutide, adjusting for age, sex, and baseline HbA1c [9]. The modest persistence advantage for tirzepatide likely reflects both its greater efficacy signal (patients who lose more weight stay motivated) and its more recent launch with active patient-support programs.

Higher persistence translates directly to better long-term durability of response: a drug that achieves 22% weight loss but is discontinued at 6 months produces worse outcomes than one achieving 10% loss maintained over three years. This is why payer programs that include structured follow-up improve real-world durability for both agents.

Summary of the Evidence Gap

The evidence base for tirzepatide on weight and glycemia is stronger in magnitude. The evidence base for dulaglutide on cardiovascular outcomes is longer in follow-up. For a 52-year-old patient with class II obesity, HbA1c of 8.4%, and no prior cardiovascular events, tirzepatide 15 mg targeting 20% or more weight loss and HbA1c below 7% is the pharmacologically superior choice based on available trial data. For a 68-year-old with established coronary artery disease, existing stable HbA1c of 7.1%, and a formulary that covers dulaglutide without prior authorization, the switch to tirzepatide may add little net benefit relative to switching cost and titration-period GI disruption.

The ADA's Standards of Medical Care in Diabetes, 2024 states directly: "For adults with type 2 diabetes and overweight or obesity, GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists with the greatest effect on body weight are preferred when weight loss is a primary therapeutic goal" [5]. Tirzepatide is currently the only dual GIP/GLP-1 agent in that category.